ARTICLE | Clinical News
Lirilumab: Phase II ongoing
October 10, 2016 7:00 AM UTC
A DSMB recommended for the seventh time continuation of the double-blind, placebo-controlled, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab based on a safety analysis. The trial completed enrollment of about 150 patients in 2014. ...